

# Sandra Tuyyaerts

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7782011/sandra-tuyyaerts-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

41  
papers

1,920  
citations

23  
h-index

43  
g-index

47  
ext. papers

2,182  
ext. citations

5.8  
avg. IF

4.2  
L-index

#	Paper	IF	Citations
41	Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 733506	8.4	1
40	Endometrial Cancer Molecular Characterization: The Key to Identifying High-Risk Patients and Defining Guidelines for Clinical Decision-Making?. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
39	Predicting combinations of immunomodulators to enhance dendritic cell-based vaccination based on a hybrid experimental and computational platform. <i>Computational and Structural Biotechnology Journal</i> , <b>2020</b> , 18, 2217-2227	6.8	
38	Biological Function of PD-L2 and Correlation With Overall Survival in Type II Endometrial Cancer. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 538064	5.3	3
37	Intratumoral Combinatorial Administration of CD1c (BDCA-1) Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial. <i>Vaccines</i> , <b>2020</b> , 8,	5.3	7
36	The Effects of Cannabidiol and Prognostic Role of TRPV2 in Human Endometrial Cancer. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	15
35	The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 1073	5.3	16
34	PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer. <i>BMC Cancer</i> , <b>2019</b> , 19, 506	4.8	26
33	Contribution of Aging, Obesity, and Microbiota on Tumor Immunotherapy Efficacy and Toxicity. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	14
32	Acute Drug Effects on the Human Placental Tissue: The Development of a Placental Murine Xenograft Model. <i>Reproductive Sciences</i> , <b>2018</b> , 25, 1637-1648	3	
31	Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	205
30	A Phase 2 Study to Assess the Immunomodulatory Capacity of a Lecithin-based Delivery System of Curcumin in Endometrial Cancer. <i>Frontiers in Nutrition</i> , <b>2018</b> , 5, 138	6.2	20
29	Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy. <i>Vaccines</i> , <b>2018</b> , 6,	5.3	2
28	mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L, and CD70). <i>Methods in Molecular Biology</i> , <b>2016</b> , 1428, 277-83	1.4	3
27	In Vitro Validation of Survivin as Target Tumor-associated Antigen for Immunotherapy in Uterine Cancer. <i>Journal of Immunotherapy</i> , <b>2015</b> , 38, 239-49	5	7
26	Potential Therapeutic Targets in Uterine Sarcomas. <i>Sarcoma</i> , <b>2015</b> , 2015, 243298	3.1	30
25	The immune system in the normal endometrium and implications for endometrial cancer development. <i>Journal of Reproductive Immunology</i> , <b>2015</b> , 109, 7-16	4.2	41

24	Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlations. <i>Journal of Translational Medicine</i> , <b>2014</b> , 12, 179	8.5	12
23	Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , <b>2014</b> , 63, 545-57	7.4	76
22	Dendritic cell immunotherapy in uterine cancer. <i>Human Vaccines and Immunotherapeutics</i> , <b>2014</b> , 10, 1822-7	4	2
21	Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma. <i>Anticancer Research</i> , <b>2013</b> , 33, 3855-9	2.3	29
20	WilmsTumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial. <i>Anticancer Research</i> , <b>2013</b> , 33, 5495-500	2.3	31
19	Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens. <i>Journal of Immunological Methods</i> , <b>2012</b> , 377, 23-36	2.5	24
18	Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. <i>Journal of Immunotherapy</i> , <b>2011</b> , 34, 448-56	5	110
17	Dendritic cell therapy for oncology roundtable conference. <i>Journal of Immune Based Therapies and Vaccines</i> , <b>2011</b> , 9, 1		5
16	Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 3366-75	12.9	130
15	Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. <i>Molecular Therapy</i> , <b>2008</b> , 16, 1170-80	11.7	145
14	Delivery of tumor-antigen-encoding mRNA into dendritic cells for vaccination. <i>Methods in Molecular Biology</i> , <b>2008</b> , 423, 155-63	1.4	11
13	CD83 expression on dendritic cells and T cells: correlation with effective immune responses. <i>European Journal of Immunology</i> , <b>2007</b> , 37, 686-95	6.1	148
12	Current approaches in dendritic cell generation and future implications for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , <b>2007</b> , 56, 1513-37	7.4	130
11	Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells. <i>Journal of Leukocyte Biology</i> , <b>2007</b> , 82, 93-105	6.5	46
10	Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. <i>Journal of Immunology</i> , <b>2006</b> , 177, 6769-79	5.3	45
9	Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA. <i>Gene Therapy</i> , <b>2006</b> , 13, 1027-36	4	28
8	Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. <i>Gene Therapy</i> , <b>2005</b> , 12, 772-82	4	81
7	Dendritic cells differentiated in the presence of IFN- $\beta$ and IL-3 are potent inducers of an antigen-specific CD8+ T cell response. <i>Journal of Leukocyte Biology</i> , <b>2005</b> , 78, 898-908	6.5	22

6	Activation of monocytes via the CD14 receptor leads to the enhanced lentiviral transduction of immature dendritic cells. <i>Human Gene Therapy</i> , <b>2004</b> , 15, 562-73	4.8	28
5	Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. <i>Journal of Immunology</i> , <b>2004</b> , 172, 6649-57	5.3	164
4	Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols. <i>Molecular Therapy</i> , <b>2004</b> , 10, 768-79	11.7	68
3	Induction of Influenza Matrix Protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells. <i>Cancer Gene Therapy</i> , <b>2003</b> , 10, 696-706	5.4	46
2	Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide. <i>Cancer Research</i> , <b>2003</b> , 63, 5587-94	10.1	38
1	Generation of large numbers of dendritic cells in a closed system using Cell Factories. <i>Journal of Immunological Methods</i> , <b>2002</b> , 264, 135-51	2.5	102